ZA845690B - Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis - Google Patents

Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis

Info

Publication number
ZA845690B
ZA845690B ZA845690A ZA845690A ZA845690B ZA 845690 B ZA845690 B ZA 845690B ZA 845690 A ZA845690 A ZA 845690A ZA 845690 A ZA845690 A ZA 845690A ZA 845690 B ZA845690 B ZA 845690B
Authority
ZA
South Africa
Prior art keywords
tigogenin
cellobioside
arteriosclerosis
treating hypercholesterolemia
beta
Prior art date
Application number
ZA845690A
Other languages
English (en)
Inventor
Rene M Malinow
Original Assignee
Oregon Medical Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Medical Res Found filed Critical Oregon Medical Res Found
Publication of ZA845690B publication Critical patent/ZA845690B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Cephalosporin Compounds (AREA)
ZA845690A 1984-04-20 1984-07-23 Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis ZA845690B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/602,298 US4602005A (en) 1982-05-17 1984-04-20 Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Publications (1)

Publication Number Publication Date
ZA845690B true ZA845690B (en) 1986-03-26

Family

ID=24410793

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA845690A ZA845690B (en) 1984-04-20 1984-07-23 Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis

Country Status (16)

Country Link
US (1) US4602005A (enExample)
EP (1) EP0159431B1 (enExample)
JP (1) JPS60224697A (enExample)
KR (1) KR940002114B1 (enExample)
AT (1) ATE42959T1 (enExample)
AU (1) AU580005B2 (enExample)
CA (1) CA1246544A (enExample)
DE (1) DE3478114D1 (enExample)
DK (2) DK165839C (enExample)
ES (1) ES8601233A1 (enExample)
FI (2) FI82253C (enExample)
HU (1) HUT37802A (enExample)
IE (1) IE58015B1 (enExample)
NO (1) NO842990L (enExample)
NZ (1) NZ208961A (enExample)
ZA (1) ZA845690B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
ATE165367T1 (de) * 1991-10-04 1998-05-15 Procter & Gamble Cholesterinsenkende verbindungen und verfahren zu ihrer herstellung
CA2079544A1 (en) * 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
FI942394A0 (fi) * 1991-11-25 1994-05-24 Pfizer Menetelmä steroidiperasyyliglykosidien valmistamiseksi
US5294703A (en) * 1992-05-01 1994-03-15 Eastman Kodak Company Process for preparing α-D-cellobiose octaacetate
CA2138016A1 (en) * 1992-06-26 1994-01-06 Kathleen D. Goggin Steroidal beta-o-cellobioside heptaalkanoate process
JPH07504921A (ja) 1992-06-26 1995-06-01 フアイザー・インコーポレイテツド 高コレステロール血症を治療するためのステロイドグリコシド
EP0647235B1 (en) * 1992-06-26 1997-09-17 Pfizer Inc. Process for steroidal peracyl glycosides
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
US5760009A (en) * 1993-04-28 1998-06-02 Pfizer Inc. Spirostanyl glycosidal crystalline monohydrate
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
WO1995000158A1 (en) * 1993-06-25 1995-01-05 Bio-Sphere Technology Dietary supplement incorporating beta-sitosterol and pectin
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
EP0782451A1 (en) * 1994-09-20 1997-07-09 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US6150336A (en) * 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
ES2257042T3 (es) * 1998-03-26 2006-07-16 Phytopharm Plc Esmilagenina y anzurogenina-d para el tratamiento de enfermedad de alzheimer.
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AR035739A1 (es) * 2001-01-26 2004-07-07 Schering Corp Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
KR20080077033A (ko) * 2001-01-26 2008-08-20 쉐링 코포레이션 혈관 질환을 치료하기 위한 스테롤 흡수 억제제와 심혈관제제의 조합물
IL156488A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
ATE331512T1 (de) * 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
AR034204A1 (es) * 2001-01-26 2004-02-04 Schering Corp Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
ATE345792T1 (de) * 2001-05-25 2006-12-15 Schering Corp Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002572A (es) * 2001-09-21 2004-05-31 Schering Corp Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
EP1429756B1 (en) * 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
JP2006508189A (ja) * 2002-11-06 2006-03-09 シェーリング　コーポレイション 自己免疫障害の処置のためのコレステロール吸収インヒビター
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
WO2005063790A1 (en) * 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Isolation of tigogenin pentaglycoside from chlorophytum nimonii
US7160866B2 (en) 2004-03-22 2007-01-09 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from Chlorophytum nimonii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759171A1 (de) * 1977-12-31 1979-07-12 Roecar Holdings Nv Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
US4242502A (en) * 1979-04-20 1980-12-30 United States Of America Enhancement of cholesterol combining properties of saponins
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Also Published As

Publication number Publication date
DK14892A (da) 1992-02-06
FI842935A0 (fi) 1984-07-23
ES534553A0 (es) 1985-11-16
DK165839C (da) 1993-06-21
DK361084D0 (da) 1984-07-23
EP0159431A2 (en) 1985-10-30
KR940002114B1 (ko) 1994-03-17
US4602005A (en) 1986-07-22
HUT37802A (en) 1986-02-28
DK165839B (da) 1993-01-25
FI82253B (fi) 1990-10-31
NO842990L (no) 1985-10-21
FI900531A0 (fi) 1990-02-02
IE841904L (en) 1985-10-20
ATE42959T1 (de) 1989-05-15
DE3478114D1 (en) 1989-06-15
ES8601233A1 (es) 1985-11-16
DK14892D0 (da) 1992-02-06
DK361084A (da) 1985-10-21
KR850007432A (ko) 1985-12-04
AU3097784A (en) 1985-10-24
JPS60224697A (ja) 1985-11-09
FI87792B (fi) 1992-11-13
JPH0456840B2 (enExample) 1992-09-09
EP0159431B1 (en) 1989-05-10
DK166213B (da) 1993-03-22
NZ208961A (en) 1988-01-08
FI87792C (fi) 1993-02-25
DK166213C (da) 1993-08-16
IE58015B1 (en) 1993-06-16
FI82253C (fi) 1991-02-11
AU580005B2 (en) 1988-12-22
CA1246544A (en) 1988-12-13
FI842935L (fi) 1985-10-21
EP0159431A3 (en) 1986-01-08

Similar Documents

Publication Publication Date Title
ZA845690B (en) Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis
EE03194B1 (et) Ühendid, nende kasutamine magustavate toimeainetena ja nende valmistamise meetod
IE841991L (en) Steroids
EP0326340A3 (en) Improvement in the synthesis of 6-methylene derivatives of androsta-1,4-diene-3,17-dione
KE3737A (en) N-naphthoylglycine derivatives
NZ236032A (en) Napthacenedione derivatives, their preparation and pharmaceutical compositions
WO1993025568A3 (en) Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
ATE131061T1 (de) Förderung der osteogenese durch verwendung von vitamin d-derivaten.
JPS5566580A (en) Coumarin derivative, its preparation and antiallergic agent containing the same as effective component
IE45756L (en) Process for the production of 2, 9-dioxatricyclo [4,3,1,0]¹decanes
EP0574271A3 (enExample)
FR2565584B1 (fr) Derives d'acide heptanoique, leur procede de preparation ainsi que leur utilisation
EP0324472A3 (en) Ketenedithioacetal derivatives and processes for producing the same as well as a composition containing the same
AU5512299A (en) Unsaturated oligophenol cyanates
CA2032311A1 (en) 2,19-methyleneoxy and 2,19-methylenethio bridged steroids as aromatase and 19-hydroxylase inhibitors
JPS5576864A (en) Carbostyril derivative
ES478143A1 (es) Un procedimiento para la fabricacion de compuestos heteroci-clicos nitrogenados.
GR850290B (enExample)